アジソン病の世界市場-2023年～2030年

概要

世界のアジソン病市場は、2022年に4億1,310万米ドルに達し、2023-2030年の予測期間中にCAGR 4.7％で成長し、2030年には6億4,470万米ドルに達すると予測されています。

アジソン危機は重篤な内分泌緊急事態であり、早急な認識と治療が必要です。この疾患と診断された患者は、副腎クリーゼが認識され治療されなければ致命的となる可能性があることを認識しておく必要があります。アジソン病は、自己免疫、感染症、副腎出血、浸潤など様々な要因によって引き起こされます。主に、アジソン病は、副腎皮質が十分な副腎皮質ホルモンを産生できないことによって引き起こされます。

さらに、世界のアジソン病市場は、研究開発の増加、治療法の進歩、各国の医療費の増加によって牽引されています。また、臨床試験数の増加により、新規治療法の開発が進んでおり、Teva Pharmaceuticals、Aspen Pharma、Pfizer Inc、Merck KGaAなどの競合企業が積極的に市場活動を行っている北米地域からの需要が増加しています。

ダイナミクス

アジソン病有病率の上昇がアジソン病市場の成長を牽引すると予想される

アジソン病の有病率の上昇は、予測期間中に市場を成長させる重要な要因の1つです。アジソン病はまれな自己免疫疾患であり、この疾患の有病率の増加は、市場を後押しする新規治療法の研究開発を増加させます。

例えば、National Library of Medicineに掲載された最新の論文によると、アジソン病は人口10万人あたり年間0.6人が罹患する稀な疾患です。ある時点でこの疾患に罹患している人の総数は、人口10万人当たり4人から11人です。成人では、好発年齢は30～50歳です。女性に多いです。

アジソン病に対する認識の高まりがアジソン病市場の成長を牽引すると期待される

アジソン病に対する認知度の向上は、予測期間中の市場成長を牽引する重要なキーファクターです。病気に関する一般的な認知度は、その目的で病気と診断されたすべての患者にとって重要なキーファクターですHCAフロリダヘルスケアは、4月が副腎疾患啓発月間であり、HCAフロリダサウスタンパ病院は、副腎疾患の診断と治療についての意識を高めています。

副腎疾患啓発月間は、副腎の重要な役割を強調し、疾患が疑われる場合に治療を受けるよう一般の人々を奨励するために重要です。

長期治療の必要性もアジソン病市場の成長を促進すると予想される

長期的な治療は、予測期間中の市場の成長を後押しする重要な側面の1つです。アジソン病は長期的なステロイド補充療法を必要とします。アジソン病の治療で最も広く使用されているのは、グルココルチコイドとミネラルコルチコイドの補充療法です。さらに、ヒドロコルチゾンは半減期が短く、血流に速やかに移行する能力があるため、グルココルチコイドファミリーの中で最も人気のある薬剤の一つです。さらに、デキサメタゾンやプレドニゾンなどの長時間作用型グルココルチコイドは、1日1回の投与レジメンが有効です。

アジソン病治療の進歩がアジソン病市場の成長を牽引すると期待される

進歩の高まりは、予測期間中に市場が成長するための重要な要因の1つです。アジソン病治療のために多くの新しい治療法が考案されており、細胞置換戦略は副腎不全の患者にとって最良の治療選択肢となる技術的進歩の一つです。このような戦略は、不十分なホルモンを補充するという明らかな目標を超えて、むしろHPA軸の機能を回復させ、治癒を可能にする戦略です。

アジソン病に伴う合併症が市場の成長を妨げる

アジソン病を未治療のままにしておくと、怪我、感染症、病気などの身体へのストレスの結果、アジソン危機を発症する可能性があります。通常、副腎は身体的ストレスに反応して通常の2～3倍のコルチゾールを産生します。副腎機能不全では、ストレスの結果として作られるコルチゾールの量を増やすことができないため、アジソン危機を引き起こす可能性があります。

アジソニアン・クライシスとは、低血圧、低血糖、高血糖を引き起こす、生命を脅かす状況です。早急な治療が必要です。また、フルドロコルチゾンによる過剰治療は高血圧（高血圧症）を引き起こす可能性があり、これらの合併症は予測期間中の市場成長宣言につながります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • アジソン病の有病率の上昇がアジソン病市場の成長を促進する見込み
    • アジソン病に対する認知度の上昇がアジソン病市場の成長を牽引すると期待される
    • 長期治療の必要性もアジソン病市場の成長を促進する見込み
    • アジソン病治療の進歩がアジソン病市場の成長を促進する見込み
  • 抑制要因
    • アジソン病に伴う合併症が市場の成長を妨げる
  • 機会
    • 研究開発の活発化
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 タイプ別

• 原発性副腎不全
• 二次性副腎不全
• 三次性副腎不全

第8章 薬剤クラス別

• 経口副腎皮質ステロイド薬
• 副腎皮質ステロイド注射
• ナトリウム摂取

第9章 投与経路別

• 経口
• 非経口

第10章 流通チャネル別

• 病院・診療所
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Teva Pharmaceuticals
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Ralington Pharma
• Aspen Pharma
• Pfizer Inc
• Merck KGaA
• Anant Pharmaceuticals
• Symbiotech
• Curia
• AuroPharma
• Parchem Fine & Specialty Chemicals

第14章 付録

Overview

Global Addison's Disease Market reached US$ 413.1 million in 2022 and is expected to reach US$ 644.7 million by 2030, growing with a CAGR of 4.7% during the forecast period 2023-2030.

Addison's crisis is a severe endocrine emergency immediate recognition and treatment are required. Patients diagnosed with this disease should be aware otherwise that if not recognized and treated, the adrenal crisis can be fatal. Addison's disease is caused by various factors like Autoimmune, infections, Adrenal Hemorrhage, Adrenal Hemorrhage, Infiltration and others. Mainly, Addison's disease is caused by an inability of the adrenal cortices to produce adequate adrenocortical hormones.

Furthermore, the global Addison disease market is driven by a rise in research and development, advancements in treatments and rising healthcare expenditures in the countries. Also, the rising number of clinical trials has resulted in the development of novel treatments is seeing an increase in demand from North American regions with significant competitors like Teva Pharmaceuticals, Aspen Pharma, Pfizer Inc, Merck KGaA and others actively operating in the market.

Dynamics

A Rise in the Prevalence of Addison's Disease Is Expected to Drive the Growth of The Addison's Disease Market

The rise in the prevalence of Addison's disease is one of the key factors that drive the market to grow during the forecast period. Addison's disease is a rare autoimmune disorder and the rise in the prevalence of this disease will increase the research and development of novel therapies which helps to boost the market.

For instance, according to an updated article published in the National Library of Medicine Addison's disease is a rare disease where the incidence is 0.6 per 100,000 of the population per year. The total number of people affected by this condition at a given time ranges from 4 to 11 per 100,000 of the population. In adults, the common age of presentation is 30 to 50 years. It is more common in women.

A Rise in Awareness of Addison's Diseases is Expected to Drive the Growth of The Addison's Disease Market

The rise in awareness of Addison's disease is the important key factor that drives the market to grow during the forecast period. General awareness about the diseases is an important key factor for every patient who is diagnosed with it for that purpose HCA Florida Healthcare initiated April is Adrenal Disease Awareness Month and HCA Florida South Tampa Hospital is raising awareness about the diagnosis and treatment of adrenal diseases.

With increased awareness, our community will become more knowledgeable about when to consult their physician regarding testing and treatment. adrenal disease awareness month is important because increased awareness emphasizes the vital purpose of the adrenal glands and encourages the general public to seek treatment if a disorder is suspected.

Need For Long-Term Treatment Will Also Expected to Drive the Growth of The Addison's Disease Market

Long-term treatment is one of the key aspects which boosts the market to grow during the forecast period. Addison's disease needs long-term steroid replacement therapy. The most widely used treatments for Addison's disease are glucocorticoid and mineralocorticoid replacement therapy. Furthermore, due to its short half-life and ability to rapidly enter into the bloodstream, hydrocortisone is one of the most popular medications in the glucocorticoid family. Furthermore, once-daily dosage regimens benefit from long-acting glucocorticoids such dexamethasone and prednisone.

Advancements in the Treatment of Addison's Disease are Expected to Drive the Growth of The Addison's Disease Market

The rise in advancements is one of the key factors that help the market to grow during the forecast period. Many emerging therapies have been invented for the treatment of Addison's disease where cell replacement strategies are one of the technological advancements where this would be the best therapeutic alternative for patients with adrenal insufficiency. Such a strategy would go beyond the evident goal of replacing insufficient hormones and rather allow for the restoration of the HPA axis function and a possible curative strategy.

Complications Associated with Addison's Disease Will Hamper the Market Growth

If a person is untreated with Addison's disease, a person may develop an Addisonian crisis as a result of stress on the body, such as injury, infection or illness. Typically, the adrenal glands make two or three times the usual amount of cortisol in response to physical stress. With adrenal insufficiency, not being able to increase the amount of cortisol made as a result of stress can lead to an Addisonian crisis.

An Addisonian crisis is a life-threatening situation that results in low blood pressure, low blood levels of sugar and high blood levels of potassium. It requires immediate medical care. Also, Over-treatment with fludrocortisone can cause high blood pressure (hypertension) since these complications result in the declaration of market growth during the forecast period.

Segment Analysis

The global Addison's disease market is segmented based on type, drug class, route of administration, distribution channel and region.

The Primary Adrenal Insufficiency Segment From The Type Segment Accounted For Approximately 41.7% of Addison's Disease Share

The primary adrenal insufficiency segment from the type segment accounted for 41.7% and it is expected to be dominated during the forecast period. Primary adrenal insufficiency is characterized by decreased aldosterone and cortisol production due to diminished gland function. It can either present acutely, which may present as an adrenal crisis, or it can be chronic, which is called Addison disease.

For instance, in February 2022, Diurnal Group plc, the speciality pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced that the first patient has been dosed in its Phase 2 European clinical trial of modified-release hydrocortisone (DNL-0200 - previously referred to as Chrono Cort for a line extension in adrenal insufficiency (AI).

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors such as increasing disease instances in the region, acquisition by key players, rising number of clinical trials, growing demand for new generation technologically integrated advanced therapeutic drugs for swift and long-term therapy, and a well-established healthcare infrastructure

For instance, in June 2021, Eton Pharmaceuticals, Inc, the U.S. marketer of ALKINDI SPRINKLE, a treatment for adrenocortical insufficiency in pediatric patients, announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis. ZENEO is a proprietary needleless device developed and manufactured by Crossject.

The pre-filled, single-use device propels medication through the skin in less than a tenth of a second. The device's compact form factor, simple two-step administration, and needle-free technology make it an ideal delivery system for emergency medications that need to be administered in stressful situations by non-healthcare professionals.

Competitive Landscape

The major global players in the market include: Teva Pharmaceuticals, Ralington Pharma, Aspen Pharma, Pfizer Inc, Merck KGaA, Anant Pharmaceuticals, Symbiotech, Curia, AuroPharma, Parchem fine & speciality chemicals and among others.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global Addison's disease market where although it is well established that intercurrent illness triggered adrenal decompensation leading to a diagnosis or worsening or primary adrenal insufficiency, this is the first description of a case in which SARS-CoV-2 infection/ COVID-19 unmasks Addison's disease.

According to the study titled 'COVID-19 and the Endocrine System: Exploring the Unexplored' released in May 2020, the adrenal system is one of the most severely impacted organ systems in the body during acute active infection in persons with COVID-19 infection who require hospitalization. As a result of the outbreak, businesses and other non-healthcare industries were forced to close. This had an effect on Addison's disease market.

By Type

• Primary Adrenal Insufficiency
• Secondary Adrenal Insufficiency
• Tertiary Adrenal Insufficiency

By Drug Class

• Oral Corticosteroid
  • Hydrocortisone
  • Fludrocortisone

• Corticosteroid Injections
• Sodium Intake

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2022, ANI Pharmaceuticals, Inc announced that the Company received U.S. Food and Drug Administration ("FDA") approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg. ANI's Fludrocortisone Acetate Tablets are the generic version of the Reference Listed Drug (RLD) Florinef.
• In April 2022, Diurnal Group extended its distribution agreement with Er-Kim to include the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsule) in Greece, Cyprus and Malta.
• In January 2022, Antares Pharma announced that the United States Food and Drug Administration had granted Fast Track designation for ATRS-1902 for adrenal crisis rescue in adults and adolescents using the company's Vai novel proprietary auto-injector platform to deliver a stable liquid formulation of hydrocortisone.

Why Purchase the Report?

• To visualize the global Addison's Disease market segmentation based on type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Addison's disease market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Global Addison's Disease market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Addison's Disease Is Expected to Drive the Growth of Addison's Disease Market.
    • 4.1.1.2. Rise in Awareness of Addison Diseases Is Expected to Drive the Growth of The Addison's Disease Market
    • 4.1.1.3. Need For Long-Term Treatment Will Also Expected to Drive the Growth of The Addison's Disease Market
    • 4.1.1.4. Advancements in Treatment of Addison's Disease is Expected to Drive the Growth of The Addison's Disease Market
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with Addison's Disease Will Hamper the Market Growth
  • 4.1.3. Opportunity
    • 4.1.3.1. Rise in Research and Development
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Primary Adrenal Insufficiency*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Secondary Adrenal Insufficiency
• 7.4. Tertiary Adrenal Insufficiency

8. By Drug Class

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.1.2. Market Attractiveness Index, By Drug Class
• 8.2. Oral Corticosteroid*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Corticosteroid Injections
• 8.4. Sodium Intake

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Parenteral

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospitals and Clinics *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Russia
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Teva Pharmaceuticals*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Ralington Pharma
• 13.3. Aspen Pharma
• 13.4. Pfizer Inc
• 13.5. Merck KGaA
• 13.6. Anant Pharmaceuticals
• 13.7. Symbiotech
• 13.8. Curia
• 13.9. AuroPharma
• 13.10. Parchem Fine & Specialty Chemicals

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us